Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and...
September 03, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Participate in Upcoming Investor Conferences in September

ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today...
August 28, 2024 20:59 ET | Source: GeoVax, Inc.

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious...
August 21, 2024 09:00 ET | Source: GeoVax, Inc.

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax...
August 15, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) --...
August 08, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
April 04, 2024 12:30 ET | Source: GeoVax, Inc.

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
March 28, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
January 04, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via...
December 19, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...

Next Page keyboard_arrow_right